Year-end inventory of hot events in the pharmaceutical industry in 2021

Looking back at the pharmaceutical industry in 2021, there have been many hot events
.
Including the monopoly of raw materials medicines issued a 100 million yuan fine; the sixth batch of special collections landed, and the price of insulin was greatly reduced; the results of the new round of medical insurance negotiations were released, and the rare disease drugs that used to be "700,000 per shot" will be about 30,000 yuan.
.
.
.
.
.
As a year-end inventory, the author selected 4 major events from them and tried to record 2021, which belongs to the pharmaceutical industry
.
Year-end inventoryHot events in the pharmaceutical industry in 2021 (Source: Pharmaceutical Network) API monopoly issued a 100 million yuan fine.
In early 2021, the State Municipal Supervision Bureau issued the first 100 million yuan fine for API monopoly in 2021 and pointed out a certain drug.
Enterprises abused their dominant position in the sales market of China's Batroxobin concentrate API to implement "no-deal" monopolies
.
According to the penalty decision, the pharmaceutical company was fined 100.
7 million yuan
.
Since the beginning of this year, there are not a few companies that have been fined due to the monopoly of APIs, and the fines amounted to one million yuan at every turn
.
In November 2021, the National Anti-Monopoly Bureau was officially listed and issued the "Anti-Monopoly Guidelines on the Field of APIs" (hereinafter referred to as the Anti-Monopoly Guidelines), which also means that the supervision of the API industry will be further tightened
.
Short comment: In recent years, monopolistic behavior in the pharmaceutical industry has repeatedly occurred.
Now antitrust has entered the field of preparations from the raw material drug field.
With the release of more new regulations and policies, the pharmaceutical industry will have stricter supervision and penalties on monopolistic behavior in the future
.
In this context, pharmaceutical companies need to pay great attention to it, and only by operating in compliance can they go further
.
Insulin price cuts On November 30, the sixth batch of centralized procurement for insulin was selected in Shanghai
.
The centralized procurement is divided into 6 procurement groups of mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues
.
After the announcement of the results of the election, it attracted great attention from the industry
.
A total of 42 drugs were selected for this centralized procurement, involving 14 selected companies, including Tonghua Dongbao, Zhuhai Federation, Ganli Pharmaceutical, Dongyang Sunshine, Jiangsu Wanbang Biochemical and other local pharmaceutical companies, as well as Novo Nordisk, Sanofi, Eli Lilly and other multinational pharmaceutical companies
.
Among them, Novo Nordisk's selected products are as high as 7 with an average drop of 40.
66%; Ganli Pharmaceutical and Zhuhai Federation have both won 6; Tonghua Dongbao and Eli Lilly also have 5 each
.
Short comment: One of the purposes of centralized procurement is to benefit patients by lowering the price of medicines and make them affordable
.
The participation in the centralized procurement of insulin will not only help reduce the burden of insulin-dependent diabetes patients’ drug costs, but will also be expected to accelerate the replacement of imported insulin by domestically produced insulin
.
The rare disease drugs that used to be "700,000 a shot" were included in the medical insurance.
On December 3, the results of the much-watched 2021 medical insurance negotiation catalogue were announced
.
There are 74 new drugs this time, involving the treatment of tumors, chronic diseases, anti-infection, and rare diseases
.
Among them, 67 are exclusive drugs outside the catalog, with an average price reduction of 61.
71%.
This result will be implemented on January 1, 2022
.
This negotiation is expected to reduce the burden of patients by more than 30 billion yuan in 2022
.
Among the new drugs, expensive drugs have attracted much attention.
Among them, the rare disease drug Noxinagen sodium, which used to be "700,000 a shot", and the Bray disease treatment drug agalsidase alpha, which has an annual cost of up to one million yuan, etc.
The news of including medical insurance has aroused a high degree of heated discussion in the industry
.
Short comment: For the majority of cancer patients and patients with rare diseases, in the past, there were generally unavailable or unavailable medicines.
Even when medicines were available, the expensive expenses made the families of patients discouraged
.
With the advancement of centralized procurement and medical insurance negotiations, more expensive drugs will be included in medical insurance, which will greatly reduce the burden on patients and improve the quality of life of patients
.
Nearly 80% of the prices of Chinese medicinal materials have risen since the second half of the year, news of the prices of Chinese medicinal materials and proprietary Chinese medicines has continued to attract people's attention
.
Both Beijing Tongrentang and Jiuzhitang have reported that the prices of proprietary Chinese medicines have increased
.
In addition, in December, there are many common varieties of Chinese medicinal materials that are still increasing in price, such as coptis, honeysuckle, scutellaria, etc.
, as well as tangerine peel, dendrobium and other new medicinal and food homologous varieties.
These varieties have increased by about 10% to Between 20%
.
And even in the case of rising prices, the supply of medicinal materials is still in short supply
.
Short comment: The analysis believes that the rising raw materials of Chinese medicinal materials, the shortage of supply, and the natural environment are the main reasons for the rise of drug prices.
In order to maintain profits, relevant Chinese medicine companies have to change their product pricing strategies
.
However, for consumers, the price increase of Chinese medicine also affects the burden of drug costs, and there may even be cases in which patients cannot afford the medicine
.
Therefore, how to increase the management and supervision of drug prices in our country is also a long-term task that needs to be carried out in our country
.